Las personas que tienen un IMC de ms de 30 tienen una indicacin de tratamiento farmacolgico, adems de las pautas higinico-dietticas (alimentacin y actividad fsica)
Having a weight management plan in place may help you maintain a healthy body weight beyond your treatment
Thank you for your feedback, we appreciate it
A real-world study published in JAMA Network Open found that patients lost an average of 5.9% of body weight by the three-month mark, which translates to about 6.7 kg (roughly 15 pounds) for the average participant
Tirzepatide is a dual-agonist , meaning it works by targeting two hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Retatrutide is a triple-agonist , meaning it targets three hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Glucagon: affects energy use and fat metabolism Early studies show that retatrutide may be more successful than tirzepatide at managing diabetic kidney disease, as well as for weight control, while tirzepatide may be better at managing blood glucose
Dec 2015;133(12):1415-1424
